
## Ernest H Law

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5320763/publications.pdf Version: 2024-02-01



FDNEST H LAW

#	Article	IF	CITATIONS
1	United States Valuation of EQ-5D-5L Health States Using an International Protocol. Value in Health, 2019, 22, 931-941.	0.3	204
2	Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. Value in Health, 2020, 23, 1235-1245.	0.3	58
3	Corticosteroids in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Annals of Pharmacotherapy, 2015, 49, 335-342.	1.9	43
4	Association Between Proton Pump Inhibitors and Microscopic Colitis. Annals of Pharmacotherapy, 2017, 51, 253-263.	1.9	39
5	Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with TypeÂ2 Diabetes: A Retrospective Observational Study. Diabetes Therapy, 2017, 8, 555-571.	2.5	30
6	Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis. Breast, 2021, 57, 5-17.	2.2	28
7	Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets. Medical Decision Making, 2018, 38, 968-982.	2.4	25
8	Racial and ethnic differences in risk of second primary cancers among breast cancer survivors. Breast Cancer Research and Treatment, 2015, 151, 687-696.	2.5	21
9	A comparison of self-rated health using EQ-5D VAS in the United States in 2002 and 2017. Quality of Life Research, 2019, 28, 3065-3069.	3.1	14
10	Reply: Association Between Proton Pump Inhibitors and Microscopic Colitis: Implications for Practice and Future Research. Annals of Pharmacotherapy, 2017, 51, 719-719.	1.9	13
11	Choice Blindness and Health-State Choices among Adolescents and Adults. Medical Decision Making, 2017, 37, 680-687.	2.4	6
12	Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment. Patient Preference and Adherence, 2021, Volume 15, 611-623.	1.8	6
13	Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points. Journal of Comparative Effectiveness Research, 2022, 11, 109-120.	1.4	6
14	Target-specific oral anticoagulants in patients undergoing cardioversion. American Journal of Health-System Pharmacy, 2014, 71, 1171-1176.	1.0	4
15	The Role of Personality in Treatment-Related Outcome Preferences Among Pharmacy Students. American Journal of Pharmaceutical Education, 2019, 83, 6891.	2.1	4
16	Population-based recurrence rates among older women with HR-positive, HER2-negative early breast cancer: Clinical risk factors, frailty status, and differences by race. Breast, 2021, 59, 367-375.	2.2	3
17	Evaluation of patients with type 2 diabetes mellitus receiving treatment during the pre-diabetes period: Is early treatment associated with improved outcomes?. Diabetes Research and Clinical Practice, 2016, 122, 162-169.	2.8	1
18	Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran. Drug Design, Development and Therapy, 2015, 9, 3557.	4.3	0

#	Article	IF	CITATIONS
19	Voice Analysis of Cancer Experiences Among Patients With Breast Cancer: VOICE-BC. Journal of Patient Experience, 2021, 8, 237437352110480.	0.9	0
20	Time-Specific Differences in Stated Preferences for Health in the United States. Medical Care, 2022, Publish Ahead of Print, .	2.4	0
21	Health-related Quality of Life in Hormone Receptor-Positive Early Breast Cancer: Analyses From the Surveillance, Epidemiology, and End Results Medicare Health Outcomes Survey. Journal of Patient Experience, 2022, 9, 237437352211130.	0.9	0